ArticleNature2020
cDC1 prime and are licensed by CD4
Abstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 399 papers.
0numbers the graph read from it
0cells of the map it votes in
399citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
399 citing papers in PubMed.
- Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy.Nature communications · 2025Trial
- UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity.Cell reports. Medicine · 2025Trial
- Metabolic reprogramming in cancer-associated fibroblasts: orchestrating the tumor immune microenvironment and response to immune checkpoint blockade.Experimental hematology & oncology · 2026Review
- Article
- Magnetically Guided Macrophage Immunobots Coordinate Iron-Metabolic Cascades and Immunogenic Ferroptosis for Tumor Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Efficient generation of human cDC1-like cells to detect and enhance tumor-reactive T cells via CD4Cell reports methods · 2026Article
- Distinct migratory dendritic cell subsets cooperate to prime tissue-resident memory-like CD8⁺ T cells in mouse tumors.Nature communications · 2026Article
- Engineered probiotics for tumor-targeted combination chemoimmunotherapy.Science translational medicine · 2026Article
- Article
- Advances in Exercise-Mediated Regulation of the Gut Microbiota via the Muscle-Gut Axis: Implications for Tumor Immunity and Treatment Responses.Metabolites · 2026Review
- Mucosal immunity: mechanism and application in cancer immunotherapy.Journal of hematology & oncology · 2026Review
- Fc-optimized GITR antibody enhances a CD4 T cell-dendritic cell crosstalk to promote antitumor immunity.Nature cancer · 2026Article
- 25 Years of Cancer Immunoediting: Dendritic Cells and Macrophages Filled the Missing Gap.Cancers · 2026Review
- Antigen presentation requirements for effective cDC1-based cancer immunotherapy.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Ecosystem-matched reprogramming of the tumor-immune microenvironment to overcome cancer immunotherapy resistance.Molecular cancer · 2026Review
- Resetting the immune setpoint of cold tumors through a ferroptosis-cGAS-STING amplification circuit.Journal of translational medicine · 2026Review
- Dendritic cell redundancy enables priming of anti-tumor CD4Cancer cell · 2026Article
- Spatial organization of the TNBC tumor microenvironment: multicellular niches, T-cell bottlenecks, and therapeutic opportunities.Journal of translational medicine · 2026Review
- In vivo engineering tumor cells to a universal "all-in-one" cancer vaccine with full antigen spectrum.Science advances · 2026Article
- Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L-CD40 Pathway.Cancer immunology research · 2026Article
339 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
17 authors.
Stephen T Ferris *Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0003-3340-2607
Vivek Durai *Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Renee Wu *Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Derek J TheisenDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Jeffrey P WardDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Michael D BernDivision of Rheumatology, Washington University School of Medicine, St Louis, MO, USA.
Jesse T DavidsonDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0003-1099-8444
Prachi BagadiaDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Tiantian LiuDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Carlos G BriseñoDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Lijin LiDepartment of Surgery, Washington University School of Medicine, St Louis, MO, USA.
William E GillandersDepartment of Surgery, Washington University School of Medicine, St Louis, MO, USA.
Gregory F WuDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Wayne M YokoyamaDivision of Rheumatology, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0002-0566-7264
Theresa L MurphyDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Robert D SchreiberDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Kenneth M MurphyDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA. kmurphy@wustl.edu.ORCID http://orcid.org/0000-0002-3505-9630
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0MWU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8MWashington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4MTRAINING PROGRAM IN IMMUNOLOGY AND IMMUNOGENETICST32AI007163 · NIAID · WASHINGTON UNIVERSITY · PI Kenneth M Murphy, Kodi S Ravichandran · 1985 to 2026
$14.8MSURGICAL ONCOLOGY TRAINING GRANTT32CA009621 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN, William E. Gillanders · 1988 to 2026
$12.9MWashington University Rheumatic DiseasesResearch Resource-based CenterP30AR073752 · NIAMS · WASHINGTON UNIVERSITY · PI Christine T. Pham · 2018 to 2026
$7.6MNatural Killer Cell Tolerance to SelfR01AI129545 · NIAID · WASHINGTON UNIVERSITY · PI Wayne M. Yokoyama · 2017 to 2026
$5.5MMolecular Basis of cDC1 DevelopmentR01AI162643 · NIAID · WASHINGTON UNIVERSITY · PI MURPHY, KENNETH M · 2022 to 2025
$2.8MFunction of Wdfy4 in cross-presentation and immunityR01AI150297 · NIAID · WASHINGTON UNIVERSITY · PI MURPHY, KENNETH M · 2019 to 2023
$2.5MUnderstanding the Mechanisms of DC Licensing in CD8 T Cell PrimingR01CA248919 · NCI · WASHINGTON UNIVERSITY · PI MURPHY, KENNETH M · 2021 to 2025
$2.3MDEVELOPMENT OF GENOMICS BASED PERSONALIZED CANCER IMMUNOTHERAPYR01CA190700 · NCI · WASHINGTON UNIVERSITY · PI SCHREIBER, ROBERT DAVID · 2015 to 2019
$2.1MThe Role of TRPV4 in central nervous system immunity and diseaseR01NS106289 · NINDS · WASHINGTON UNIVERSITY · PI WU, GREGORY · 2018 to 2021
$1.6MHoward Hughes Medical InstituteNCATS NIH HHS UL1 TR000448NCATS NIH HHS UL1 TR002345NCI NIH HHS P30 CA091842NCI NIH HHS R01 CA190700NCI NIH HHS R01 CA248919NCI NIH HHS T32 CA009573NCI NIH HHS T32 CA009621NIAID NIH HHS R01 AI129545NIAID NIH HHS R01 AI150297NIAID NIH HHS R01 AI162643NIAID NIH HHS T32 AI007163NIAMS NIH HHS P30 AR073752NIDDK NIH HHS F30 DK108498NIDDK NIH HHS F30 DK112466NINDS NIH HHS R01 NS106289
Abstract
Conventional type 1 dendritic cells (cDC1)
Indexed as
Cross-PrimingAnimalsAntigen PresentationCD40 AntigensCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDendritic CellsFemaleHistocompatibility Antigens Class IIMiceNeoplasmsSignal TransductionCD40 AntigensHistocompatibility Antigens Class II
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.